Loading...
XASXCUV
Market cap378mUSD
Dec 23, Last price  
12.11AUD
1D
0.75%
1Q
-15.67%
Jan 2017
62.55%
Name

Clinuvel Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:CUV chart
P/E
17.01
P/S
6.88
EPS
0.71
Div Yield, %
0.41%
Shrs. gr., 5y
0.57%
Rev. gr., 5y
23.22%
Revenues
88m
+12.59%
124,622754,846283,3080001,041,021722,8011,552,9982,663,1103,317,6796,820,39816,765,45625,485,82031,047,77632,565,42347,975,58365,722,29178,321,31888,178,308
Net income
36m
+16.44%
-11,029,031-10,768,981-9,176,123-14,655,791-15,372,907-11,521,040-11,409,089-9,767,228-6,802,823-5,525,889-10,398,033-3,121,2007,180,82713,224,18518,134,16016,646,85924,728,24720,878,46530,604,56635,636,359
CFO
37m
+0.38%
-9,246,356-11,403,457-8,178,814-7,181,333-10,985,544-11,782,745-9,486,857-10,022,681-6,892,066-4,808,685-4,529,812-5,036,9339,916,93611,693,33318,456,10714,188,36819,262,06139,872,28236,912,06337,053,882
Dividend
Sep 05, 20240.05 AUD/sh
Earnings
Feb 20, 2025

Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
URL
https://www.clinuvel.com/
IPO date
Feb 13, 2001
Employees
16
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
88,178
12.59%
78,321
19.17%
65,722
36.99%
Cost of revenue
39,030
37,412
32,639
Unusual Expense (Income)
NOPBT
49,148
40,910
33,083
NOPBT Margin
55.74%
52.23%
50.34%
Operating Taxes
15,043
14,974
13,442
Tax Rate
30.61%
36.60%
40.63%
NOPAT
34,106
25,936
19,641
Net income
35,636
16.44%
30,605
46.58%
20,878
-15.57%
Dividends
(2,470)
(1,976)
(1,235)
Dividend yield
0.31%
0.21%
0.16%
Proceeds from repurchase of equity
(754)
BB yield
0.10%
Debt
Debt current
370
(15,793)
315
Long-term debt
1,390
1,398
1,883
Deferred revenue
Other long-term liabilities
164
3,700
102
Net debt
(182,243)
(174,060)
(122,012)
Cash flow
Cash from operating activities
37,054
36,912
39,872
CAPEX
(5,576)
(1,028)
(434)
Cash from investing activities
(29,034)
(1,028)
(434)
Cash from financing activities
(3,572)
(2,240)
(1,504)
FCF
23,737
7,736
25,596
Balance
Cash
183,868
156,814
121,509
Long term investments
134
2,851
2,700
Excess cash
179,594
155,749
120,924
Stockholders' equity
203,011
164,631
125,559
Invested Capital
24,461
10,014
(1,286)
ROIC
197.86%
594.33%
246.47%
ROCE
23.83%
24.16%
26.65%
EV
Common stock shares outstanding
51,027
51,816
51,776
Price
15.37
-14.04%
17.88
20.40%
14.85
-51.63%
Market cap
784,281
-15.35%
926,470
20.50%
768,880
-51.02%
EV
602,037
752,410
646,869
EBITDA
50,290
41,699
33,841
EV/EBITDA
11.97
18.04
19.11
Interest
4,454
3,193
2,274
Interest/NOPBT
9.06%
7.80%
6.87%